We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

STANDARD DIAGNOSTICS INC.

Standard Diagnostics develops rapid diagnostic tests that make it possible to diagnose various diseases at an earlier... read more Featured Products: More products

Download Mobile App




Immuno-Magnetic Agglutination Assay Detects Dengue Virus Antigen

By LabMedica International staff writers
Posted on 09 Mar 2020
Print article
Image: The ViroTrack Dengue Acute assay is a rapid and semi-quantitative microfluidic Dengue virus (DENV) NS1 detection method based on immuno-magnetic agglutination (IMA) technology (Photo courtesy of BluSense Diagnostics).
Image: The ViroTrack Dengue Acute assay is a rapid and semi-quantitative microfluidic Dengue virus (DENV) NS1 detection method based on immuno-magnetic agglutination (IMA) technology (Photo courtesy of BluSense Diagnostics).
Dengue virus (DENV) is the most important arbovirus worldwide, causing infections in endemic countries and returning travellers from these areas. Rapid diagnostic tests are needed to improve patient management and monitor local transmission. The detection of DENV non-structural protein 1 (NS1) is a useful tool for the diagnosis.

Immuno-magnetic agglutination (IMA) assays are newly developed methods that use magnetic particles coated with capture molecules (e.g. antibodies, ligands, nucleotides) that bind specifically to the target biomarker, forming clusters that enable the detection. Different assays have been developed for the detection of pathogens, small molecules and proteins.

Clinical microbiologists at the Hospital Clinic of Barcelona (Barcelona, Spain) and their colleagues analyzed a panel of 135 serum samples from travelers returning from dengue endemic countries: 74 DENV positive samples including the four DENV serotypes, 26 Zika virus positive samples, 25 chikungunya virus positive samples, five malaria positive samples and five negative samples.

The team tested the samples by three different methods for detection of DENV NS1 antigen: SD Dengue NS1 Ag ELISA is an enzyme-linked immunosorbent assay for the qualitative detection of NS1 antigen in human serum (Standard Diagnostic Inc, Yongin, Korea), SD BIOLINE Dengue Duo is a rapid immunochromatographic test (ICT) that detects both DENV NS1 antigen and antibodies against DENV (IgM/IgG) in human serum, plasma or whole blood, and ViroTrack Dengue Acute, a rapid and semi-quantitative microfluidic DENV NS1 detection method based on IMA technology (BluSense Diagnostics, Copenhagen, Denmark).

The scientists reported that sensitivity values were higher with the ELISA (97.2%), followed by the IMA assay (91.9%) and the ICT (68.1%). Specificity was 100% for ELISA and ICT and 98.4% for the IMA test. One ZIKV positive sample tested positive in IMA assay. This sample was obtained two days after the onset of the symptoms and tested positive for ZIKV and negative for DENV and CHIKV by real-time RT-PCR. This apparent cross-reactivity was not observed in the other 25 ZIKV positive samples tested. All methods showed high specificity (98.4% for ViroTrack Dengue Acute and 100% for both SD Dengue NS1 Ag ELISA and SD BIOLINE Dengue Duo). SD Dengue NS1 Ag ELISA and ViroTrack Dengue Acute only failed to detect a samples positive for DENV-2.

The authors concluded that ViroTrack Dengue Acute is a sensitive and specific assay for DENV NS1 detection. It provides faster results than the ELISA method and a better performance than the rapid immunochromatographic tests. ViroTrack Dengue Acute could represent a valuable tool for rapid diagnosis of DENV infections in returning travellers from endemic countries. The study was published on February 18, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Hospital Clinic of Barcelona
Standard Diagnostic Inc
BluSense Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.